"Gene Amplification" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication.
| Descriptor ID |
D005784
|
| MeSH Number(s) |
G05.308.250 G05.365.590.310 G05.558.315
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Gene Amplification".
Below are MeSH descriptors whose meaning is more specific than "Gene Amplification".
This graph shows the total number of publications written about "Gene Amplification" by people in this website by year, and whether "Gene Amplification" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 2 | 3 |
| 1994 | 0 | 2 | 2 |
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 2 | 2 |
| 1998 | 0 | 3 | 3 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 3 | 3 |
| 2004 | 0 | 3 | 3 |
| 2006 | 1 | 3 | 4 |
| 2007 | 0 | 5 | 5 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 4 | 4 |
| 2010 | 0 | 1 | 1 |
| 2011 | 3 | 1 | 4 |
| 2012 | 3 | 0 | 3 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 3 | 5 |
| 2015 | 0 | 3 | 3 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 3 | 4 |
| 2018 | 2 | 3 | 5 |
| 2019 | 0 | 2 | 2 |
| 2020 | 0 | 3 | 3 |
| 2021 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Gene Amplification" by people in Profiles.
-
Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. JCO Precis Oncol. 2023 03; 7:e2200334.
-
Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group. Am J Surg Pathol. 2021 08 01; 45(8):1075-1081.
-
Clinical Validation of Whole Genome Sequencing for Cancer Diagnostics. J Mol Diagn. 2021 07; 23(7):816-833.
-
A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2021 03; 68(3):e28794.
-
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. J Clin Oncol. 2020 11 01; 38(31):3685-3697.
-
The force of HER2 - A druggable target in NSCLC? Cancer Treat Rev. 2020 Jun; 86:101996.
-
Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. Clin Cancer Res. 2020 01 15; 26(2):354-363.
-
SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). J Thorac Oncol. 2019 10; 14(10):1847-1852.
-
Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. Future Oncol. 2019 Jun; 15(18):2073-2082.
-
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. Neuro Oncol. 2019 01 01; 21(1):106-114.